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Abstract Recent studies have demonstrated elevated
levels of iron (Fe) in brains of patients with Huntington’s
disease (HD). Striatal cells carrying mutated Huntingtin
presented increased sensitivity to cadmium (Cd) toxicity,
decreased sensitivity to manganese (Mn) toxicity and def-
icits in Mn uptake. The hypothesis arose that the observed
alterations result from the altered expression and/or activity
of proteins engaged in the transport of these metals, that is:
transferrin (TF), transferrin receptor (TFR), divalent metal
transporter 1 (DMT1) and ZIP8 protein. Here we examined
the expression levels of genes encoding these proteins in
blood of HD patients and control subjects. A decreasing
tendency in the level of TF transcript and increasing ten-
dency of SLC11A2 mRNA encoding DMT1 was observed
in the blood of HD patients compared to the control sub-
jects, but neither attained statistical significance. No
changes were found in the levels of TFRC coding for TFR
and SLC39A8 coding for ZIP8 between HD patients and
controls. The results indicate that HD-associated changes
in metal homeostasis occur are not related to mechanisms
other than the expression level of the here analyzed metal
transporters.
Keywords Huntington’s disease  Metal transporter  TF 
TFR  DMT1  ZIP8
Introduction
Huntington’s disease (HD) is a chronic and progressive
neurodegenerative disease clinically characterized by
chorea, psychiatric, psychological and intellectual disor-
ders, and neuropathologically by the loss of striatal pro-
jection neurons [1]. Currently, there is no effective
treatment to delay the onset or significantly slow the pro-
gression of HD. HD is an autosomal-dominant disorder
caused by mutation of the IT15 gene (also known as HTT)
encoding huntingtin (Htt). The detailed role of wild-type
Htt is unclear, although a growing body of studies indicates
its function in brain development and embryogenesis [2],
autophagy [3], and regulation of gene transcription [4, 5]. It
also protects against cell death and has anti-apoptotic
properties [6, 7]. Huntingtin knockout mice exhibit
embryonic lethality [8]. Wild-type human Htt contains the
polyQ domain composed of 11–34 glutamine (CAG) resi-
dues. HD is caused by an abnormal ([35) expansion of the
CAG repeats [1]. Proteolysis of mutant Htt (mHtt) releases
multiple N-terminal Htt fragments containing expanded
polyQ repeats which aggregate in nucleus and cytoplasm of
affected neurons [9]. It is still unclear whether the aggre-
gates are cytotoxic per se, although the cytotoxic effect of
mHtt have been documented in distinct HD models [10].
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Recent findings identified several proteins interacting with
mHtt which may contribute to the pathology of HD [9].
Lack of correlation between the selective degeneration
and widespread expression of mHtt strongly suggests that
other factors may increase the vulnerability of striatal
neurons to the pathophysiological mechanisms underlying
HD [11, 12]. Growing evidence links HD to altered metal
homeostasis. Increased levels of iron (Fe) and copper (Cu)
were found in postmortem brain tissue from patients with
HD compared with control subjects [13–15]. Studies on a
mutant STHdhQ111/Q111 cell line, a striatal neuronal cell
line model of HD, revealed changes in Fe signaling and
elevated level of transferrin receptor (TfR) in comparison
with the wild-type STHdhQ7/Q7 cells [16]. The mutant
STHdhQ111/Q111 cells displayed an increased sensitivity to
cadmium (Cd) toxicity and resistance to manganese (Mn)
toxicity [17]. Of note, this neuroprotective interaction was
highly metal specific. Moreover, a decreased accumulation
of Mn was observed in the mutant STHdhQ111/Q111 cells
and in the YAC128Q HD mouse model [17]. The
hypothesis arose that the observed alterations result from
the altered expression of proteins engaged in the transport
of heavy metals, that is: divalent metal transporter 1
(DMT1), ZIP8 protein, transferrin (TF) and transferrin
receptor, TfR [19]. As a step towards verifying the
hypothesis, we compared the expression levels of genes




Fifteen HD patients were recruited from the Department of
Neurology, Medical University of Warsaw, Warsaw,
Poland (seven patients) and the Specialist Hospital s´w.
Wojciecha in Gdan´sk, Poland (eight patients). All patients
were positive on the molecular test for the presence of a
CAG triplet [35 repeats in the HTT gene. They also
manifested clinical signs and symptoms of HD. Clinical
examination was performed by trained [formal and certi-
fied training within the European Huntington’s Disease
Network (EHDN)] neurologists and psychologists and
included: motor and behavioural rating due to Unified
Huntington’s Disease Rating Scale (UHDRS) and neu-
ropsychological rating for depression (Hamilton and
Beck’s questionnaires), TFC (Total Functioning Capacity)
and cognitive assessment (Stroop Test, Verbal Fluency
Test, Symbol Digit Modality Test). A control group (age
and gender matched) included volunteers with no neu-
rodegenerative disorders. All of the participants received
verbal and written information about the study, and signed
an informed consent form. The local Ethics Committees
approved all procedures. Table 1 shows the subjects’
gender, age and the length of the CAG repeat on the
expanded allele.
RNA Extraction
Peripheral blood lymphocytes were isolated from blood of
patients and control subjects from the Medical University
of Warsaw, Poland. First, the blood sample was diluted
with an equal volume of phosphate buffered saline (PBS)
and poured onto the Ficoll solution (Sigma-Aldrich). The
test tube was centrifuged for 20 min at 1600 rpm. The ring
with white blood cells was harvested and washed twist with
PBS. Next, total RNA was extracted from the lymphocytes
using TRI Reagent BD (Sigma-Aldrich), according to the
manufacturer’s protocol. Total RNA was extracted from
whole blood of patients and control subjects from the
Specialist Hospital s´w. Wojciecha in Gdan´sk, Poland,
using PAXgene Blood RNA Kit (Qiagen) according to the
manufacturer’s protocol. Total RNA concentration was
measured with a NanoDrop 1000 Spectrophotometer.
Reverse Transcription and Real-Time PCR
One microgram of RNA was digested with DNaseI (Invit-
rogen) and reverse-transcribed using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according
to the manufacturer’s protocol. Two independent reverse
transcription reactions were performed for every RNA
sample. Real-time PCR was performed using TaqMan Gene
Expression Assays listed in Table 2 and TaqMan Universal
PCR Master Mix (Applied Biosystems) according to the
manufacturer’s protocol. The reactions were incubated at
95 C for 10 min, followed by 45 cycles of 95 C for 15 s
and 60 C for 1 min using an Applied Biosystems 7500
Sequence Detection System. Relative expression was nor-
malized to the expression of ACTB gene encoding b-actin
and calculated using the DDCT method [20].
Statistical Analyses
The data were analyzed using the paired Student’s t test. In
the box plots, the boundary of the box closest to zero
Table 1 Clinical and genetic characteristics of HD patients and
healthy controls
Samples No. Sex (women/men) Age (years) CAG size
Control 15 9/6 46 (27–70) –
HD 15 9/6 57 (33–78) 41 (39–51)
Age and CAG size are expressed as median values (min–max). The
number of CAG repeats is missing for 4 HD patients
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indicates the 25th percentile, the line in the middle is
plotted at the median, and the boundary of the box farthest
from zero indicates the 75th percentile. The Pearson’s
correlation coefficient was used to identify correlations
between the number of CAG repeats and the level of
SLC11A2 and TF mRNA levels normalized to ACTB
mRNA.
Results
We performed real-time PCR analysis of expression of TF,
TFRC, SLC11A2 (coding for DMT1) and SLC39A8 (coding
for ZIP8) genes in blood of HD and control subjects. A
statistically insignificant decreasing tendency in TF mRNA
level was observed in HD patients (mean value: 0.8369;
median value: 0.8285) compared to controls (mean value:
1.072; median value: 1.034) (Fig. 1a). Of note, TF mRNA
was undetectable in 3 out of 15 HD patients, therefore the
analysis of TF expression was performed on 12 HD and 12
healthy subjects. No difference was found in TFRC mRNA
level between controls (mean value: 1.080; median value:
1.109) and HD patients (mean value: 1.124; median value:
1.197) (Fig. 1b). SLC11A2 mRNA showed a tendency to
increase in HD patients (mean value: 1.748; median value:
1.428) with respect to controls (mean value: 1.259; median
value: 0.9238), although this difference was not statisti-
cally significant (p[ 0.05; Fig. 1c). There was no statis-
tically significant difference between the level of SLC39A8
transcript in controls (mean value: 1.174; median value:
1.129) and HD patients (mean value: 1.133; median value:
0.8990) (Fig. 1d).
Next we examined whether the alterations in TF and
SLC11A2 mRNA levels observed in blood of HD patients
were associated with the number of CAG repeats. As data
concerning CAG size were missing for 4 samples, this
analysis was performed on 8 and 11 samples in the case of
TF and SLC11A2 mRNA, respectively. We found no cor-
relation between the number of CAG repeats and the level
of TF (r = 0.1361, P = 0.7480, Pearson’s test) or
Table 2 TaqMan gene
expression assays used for real-
time PCR
Transcript Assay ID GeneBank sequence Exon boundary
TF Hs01067777_m1 AK222755.1 14–15
TFRC Hs00951083_m1 AB209254.1 16–17
SLC11A2 Hs00167206_m1 AB004857.1 15–16
SLC39A8 Hs00223357_m1 AB040120.1 3–4
ACTB 4326315E NM_001101.2 1
Fig. 1 Relative levels of
manganese transporters
transcripts in blood from control
and HD subjects. Levels of TF
(a), TFRC (b), SLC11A2 (c) and
SLC39A8 (d) mRNA were
normalized to beta-actin
(ACTB). HD, HD patients. The
boundary of the box closest to
zero indicates the 25th
percentile, the line in the middle
is plotted at the median, and the
boundary of the box farthest
from zero indicates the 75th
percentile
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SLC11A2 (r = -0.4429, P = 0.1725) mRNA (Fig. 2a, b,
respectively).
Discussion
Fe and Mn play roles in a number of physiological pro-
cesses, yet the exposure to excessive levels of these metals
can cause a damage to the nervous system. Association
between altered homeostasis of these metal and neurode-
generative disorders, including HD, has been frequently
postulated (for extensive reviews, please refer to [21–24]).
Alterations in Fe signaling were observed in a mutant
STHdhQ111/Q111 cell line, a striatal neuronal cell line model
of HD as compared to the wild-type STHdhQ7/Q7 cells [16].
Increased level of Fe was found in R6/2 HD mice [25] and
in brain tissue from HD patients [13–15]. Recent studies
revealed increased sensitivity of STHdhQ111/Q111 cell line
to Cd toxicity and resistance to Mn toxicity. Moreover, the
same studies showed a decreased Mn accumulation in
STHdhQ111/Q111 cells and YAC128Q HD mice following
in vivo Mn exposure [17, 18].
Here we addressed the hypothesis that disturbed Fe and
Mn homeostasis observed in HD models are caused by
changes in the function of metal-transporting proteins and
we asked the question whether this pathogenetic pattern
also holds for human HD. As a step toward this end, we
analysed the expression of genes encoding the four proteins
most evidently involved in the transport of these metals and
tightly link Fe and Mn homeostasis to each other. A
growing body of evidence suggests that transferrin (TF),
the main Fe-carrying protein in neurons [26] and trans-
ferring receptor (TFR) play crucial role in brain Mn
transport [19, 27, 28]. STHdhQ111/Q111 cells exhibit alter-
ations in the level of TFR protein: its decreased level was
found in the early passages of this cell line [16], while the
late passages presented an increased level of this protein
[18] compared with a wild-type cells STHdhQ7/Q7. While
our data demonstrate a decreasing tendency in the level of
TF transcript in the blood of HD patients compared to the
control subjects, no correlation was observed between the
relative level of TF transcript and the numbers of CAG
repeats, a hallmark of HD. We have also observed lack of
differences in the level of TFRC transcript between HD
patients and controls.
Another protein involved in Fe and Mn delivery is
DMT1 (divalent metal transporter-1, also known as
NRAMP-2) [29–31]. This protein is of interest as it has
been implicated in the transfer of Mn and other metals
across the blood–brain barrier [32]. Dysfunction of DMT1
has been linked to many disorders including Parkinson’s
[33] and Alzheimer’s [34] disease. A slight trend toward
increased DMT1 level was observed in STHdhQ111/Q111
cells compared with the wild-type cells [18]. In our study,
SLC11A2 mRNA encoding DMT1 showed a tendency to
increase in HD patients compared with controls. However,
as was the case with the TF transcript, the increase did not
reach statistical significance and the slight changes did not
correlate with the number of CAG repeats. It will have to
be verified whether the tendencies towards decrease/in-
crease noted above on the limited number of samples will
reach statistical significance when larger amounts of
material become available.
We have also examined the expression of SLC39A8
encoding ZIP8, as this protein is involved in Fe transport in
hippocampal neurons [35] and some findings suggest its
role in Mn transport [36, 37]. A point mutation p.A391T in
SLC39A8 has been associated with some disorders
including schizophrenia [38]. We have found no differ-
ences in the level of SLC39A8 transcript between the blood
of HD and control subjects.
In conclusion, our study failed to demonstrate changes
in the expression level of genes coding for the major brain
transporters of Fe and Mn: TF, TFR, DMT1 and ZIP8
between blood of HD patients and controls. If impaired
metal homeostasis in human HD is related to the dys-
function of the group of metal transporters here analyzed,
the underlying mechanisms will have to involve one or
several steps post transcription. On the other hand, evi-
dence has recently begun to accumulate suggesting a role
Fig. 2 Lack of correlation
between the numbers of CAG
repeats and the relative level of
TF (a) or SLC11A2 (b) mRNA
in blood of HD patients. As data
concerning the number of CAG
repeats were missing for 4 HD
patients, the analysis was
performed on 8 samples in case
of TF mRNA (a) and 11
samples in case of SLC11A2
mRNA (b)
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of efflux and efflux-mediating proteins in maintaining
metal homeostasis (for an exhaustive review see Ref. [32]).
The absence of changes in the expression of metal trans-
porters dealt with in the present study does not exclude
contribution of other transporting moieties that have
attracted attention more recently, such as ZIP14, DAT,
citrate transporters, Ca channels, SLC30A10 and ferro-
portin (for an exhaustive review see Ref. [32]). Most sig-
nificantly, hypermanganesemia with associated Parkinson
Disease symptoms has been found related to mutations in
the SLC30A10, a member of the SLC30 solute carrier
subfamily previously thought to serve as a specific Zn
transporter [39, 40]. In this context, analysis of the
expression and sequence of RNAs coding metal efflux-
mediating proteins in HD patients appears to be an inter-
esting venue of further investigations.
It may be argued that the results of gene expression
obtained from blood analysis may not be unconditionally
representative for the expression patterns of metal trans-
porters in the brain, a question that we were unable to
attend practically. However, numerous recent reports have
convincingly documented a good correlation between the
brain tissue and peripheral readouts of other genes pur-
portedly associated with the development of HD. Positive
correlation in this regard has been noted, for instance, for
TGF-b1 [41] and Rho kinase pathway genes [42]. Clearly,
the present results will have to be verified once access to
representative brain tissue is gained.
Irrespective of the above considerations, it appears
mandatory to use a functional approach, starting with
comparing metal transport in lymphocytes derived from
control and HD subjects.
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